MERTK and neoplasm: Moreover, treatment with MERTK kinase inhibitor MRX-2843 [67,242] re-sensitized resistant cells to osimertinib in cell-based assays and provided durable tumor regression in a mtEGFR NSCLC xenograft model, even after treatment ended [80].